Survival associations and driver oncogene overlap for copy-number amplifications of ERBB2, KRASand METin Non-small cell lung cancer


Alexander Watson, Harris Krause, Andrew Elliott, Alex Farrell, Stephen Liu, Patrick Ma, Ari Vanderwalde, George Sledge, David Spetzler, Erin Schenk, D. Camidge


  • Next-generation sequencing (NGS) is standard of care in metastatic non-small cell lung cancer (NSCLC)
  • Targeted therapy has transformed outcomes for driver mutation-positive tumors
  • Copy number amplifications (CNA) of driver oncogenes are also frequently detected via NGS -interpretation and clinical impact is less clear
  • ERBB2, KRAS and MET are oncogenic driver genes with intersecting resistance mechanisms and evolving therapeutic landscapes
Download Publication